Telephone
61.8.6151.0992
Address
6 Verdun Street Harry Perkins Institute Nedlands, Western Australia (WA) 6009
Description
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001 and is headquartered in Nedlands, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.12
Trade Value (12mth)
AU$20,318.00
1 week
4.26%
1 month
67.52%
YTD
40%
1 year
44.12%
All time high
0.656939
EPS 3 yr Growth
184.000%
EBITDA Margin
N/A
Operating Cashflow
-$24m
Free Cash Flow Return
-71.90%
ROIC
-67.10%
Interest Coverage
-1,402.90
Quick Ratio
3.80
Shares on Issue (Fully Dilluted)
3287m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 October 19 |
Entitlement Offer - Investor Presentation
×
Entitlement Offer - Investor Presentation |
31 October 17 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 October 13 |
Annual Report to shareholders
×
Annual Report to shareholders |
31 May 22 |
Corporate Presentation - May 2022
×
Corporate Presentation - May 2022 |
31 August 23 |
Appendix 4E and Audited Financial Statements
×
Appendix 4E and Audited Financial Statements |
31 August 22 |
Preliminary Final Report
×
Preliminary Final Report |
31 August 06 |
Investor Presentation
×
Investor Presentation |
30 October 06 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
30 October 06 |
Phylogica Limited - Annual Report 2006
×
Phylogica Limited - Annual Report 2006 |
30 November 23 |
Response to Price Query
×
Response to Price Query |
30 November 10 |
AGM presentation
×
AGM presentation |
30 June 23 |
FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL
×
FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL |
30 August 13 |
Appendix 4E and Audited Annual Financial Statements
×
Appendix 4E and Audited Annual Financial Statements |
29 November 22 |
PYC Increases Ownership of VP-001 Program
×
PYC Increases Ownership of VP-001 Program |
29 November 06 |
AGM Presentations
×
AGM Presentations |
29 November 06 |
Annual General Meeting Results
×
Annual General Meeting Results |
29 June 21 |
VP-002 Program - Technical Presentation
×
VP-002 Program - Technical Presentation |
29 December 21 |
Change in substantial holding
×
Change in substantial holding |
29 April 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 October 22 |
Notification regarding unquoted securities - PYC
×
Notification regarding unquoted securities - PYC |
28 October 22 |
Issue of Options
×
Issue of Options |
28 October 13 |
Investor Presentation
×
Investor Presentation |
28 October 10 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
28 October 10 |
Annual Report to shareholders
×
Annual Report to shareholders |
28 November 13 |
Presentation to Shareholders
×
Presentation to Shareholders |
28 November 07 |
AGM presentation to shareholders
×
AGM presentation to shareholders |
28 June 23 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.